Stockscreener 앱 받기
33.56
2.63%
0.86
시간 외 거래:
33.73
0.17
+0.51%
Edgewise Therapeutics Inc 주식(EWTX)의 최신 뉴스
Why (EWTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $52 - Moomoo
EWTX Stock Chart | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc.Common Stock (NQ: EWTX - The Chronicle-Journal
Janus Henderson (EWTX) reports 5.5% ownership — 5.9M shares disclosed - Stock Titan
Understanding Momentum Shifts in (EWTX) - Stock Traders Daily
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Muscle disease drug developer heads to RBC healthcare event May 20 - Stock Titan
TradingKey - TradingKey
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 - Yahoo Finance
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says - Moomoo
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Edgewise boosts R&D spending as drug trials bear promising results - BizWest
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Edgewise Therapeutics Shares Decline Amid Wider Q1 Loss - Moomoo
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q1 Net Loss $0.46 a Share, vs. FactSet Est of $0.49 Net Loss a Share - marketscreener.com
Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten - ChartMill
Edgewise Therapeutics (NASDAQ: EWTX) posts Q1 2026 net loss of $49M - Stock Titan
EDGEWISE THERAPEUTICS ($EWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Edgewise Therapeutics Q1 net loss widens on higher R&D costs - TradingView
Edgewise Therapeutics 1Q 2026: Net income $(49.0M), EPS $(0.46) — 10-Q Summary - TradingView
Edgewise Therapeutics (NASDAQ: EWTX) reports Q1 2026 loss, $499.6M cash - Stock Titan
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PR Newswire
Edgewise Therapeutics earnings on deck as losses widen By Investing.com - Investing.com Australia
Edgewise Therapeutics earnings on deck as losses widen - Investing.com
Truist Securities Adjusts Price Target on Edgewise Therapeutics to $52 From $46, Maintains Buy Rating - marketscreener.com
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary - GlobeNewswire Inc.
Edgewise Therapeutics stock hits 52-week high at $39.96 By Investing.com - Investing.com Australia
Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong Biotech Sentiment - International Business Times Australia
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock - Investing.com India
Edgewise Therapeutics Stock Climbs On Catalyst-Rich Pipeline - timothysykes.com
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
50,000-share sale notice for EWTX (NASDAQ: EWTX) - Stock Titan
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock By Investing.com - Investing.com South Africa
Raymond James Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Edgewise Therapeutics Cmo Sold Shares Worth Over $2.0M - TradingView
Edgewise Therapeutics (EWTX) CMO sells 55,230 shares under 10b5-1 plan - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Edgewise Therapeutics stock hits 52-week high at $39.96 - Investing.com
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules - TradingView
9 new Edgewise hires receive stock options for 266,000 shares - Stock Titan
0.98%
0.12%
자본화:
|
볼륨(24시간):